Skip to content
Homepage
Author:
OPKO Health, Inc.
Posted Date:
July 27, 2026
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
OPKO Health, Inc.
July 27, 2026
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
OPKO Health, Inc.
July 23, 2026
Preclinical Data for OPKO Biologics’ OPK8801001 in Acromegaly Presented at ENDO 2026
OPKO Health, Inc.
June 15, 2026
OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
OPKO Health, Inc.
May 27, 2026
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
OPKO Health, Inc.
May 25, 2026
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
OPKO Health, Inc.
May 25, 2026
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
OPKO Health, Inc.
May 24, 2026
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
OPKO Health, Inc.
May 24, 2026
OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
OPKO Health, Inc.
May 22, 2026
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
OPKO Health, Inc.
May 8, 2026
1
2
Next
